Company news

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) news

Aspire Biopharma Holdings, Inc. news releases on 6ix. Latest, Sep 8, 2026: Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood…

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) news

Press releases & updates

Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)

Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs

Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th

Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

Aspire Biopharma Issues Shareholder Letter

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

Aspire Biopharma Announces $5.0 Million Share Repurchase Program

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Aspire Biopharma Announces Reverse Stock Split

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Aspire Biopharma Provides Q3 2025 Business Update

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product